|
|
|
Xtalks, Online
2024-10-30
It is estimated that globally 1 in 8 individuals (2019 WHO figures) are affected by mental health problems, causing problems with all aspects of daily life. The personal, economic burden and associated increased risk in mortality underscore the need for the development of new and improved treatment options.
Clinical trials for psychiatry, including major depressive disorder, bipolar disorder, schizophrenia and generalized anxiety disorder, are unique and require an innovative and patient-centric approach to identification, enrollment and retention of suitable participants. This webinar will explore and discuss how to operationalize enrollment among a heterogenous group of participants, placebo response and its robust mitigation strategies to ensure a successful trial.
In this webinar, the expert speakers will explore the steps that can be made towards improving psychiatry trials, including recognizing the complexity of the population in protocol and trial design, understanding the patient’s journey to optimize patient recruitment and retention, increasing diversity and equality, minimizing bias and placebo response mitigation, patient and site education for consistency and accuracy and rater training and oversight.
Register now for the webinar to gain insights into strategies that can be followed for conducting successful psychiatry clinical trials.
Keywords: Drug Development, Clinical Research, CRO, Patient Recruitment, Clinical Data, Therapeutic Areas, CNS, Psychiatry, CNS Trials, CNS Drug Development, Neuropsychiatry
|
|
|
|
|
|
|
Organized by:
|
|
Xtalks |
|
Invited Speakers:
|
|
Dr. James Vornov, MD, PhD, Vice President, Medical Department, Medpace Ms. Jill Adkins, Sr. Director, Clinical Trial Management, Medpace Ms. Daniela Rae, MSc, RGN, IP, Advanced Clinical Practitioner, Medpace Ms. Miaesha Campbell, Sr. Director, Patient Recruitment, Medpace
|
|
|
|
|
|
Deadline for Abstracts:
|
|
2024-10-30
|
|
|
|
|
|
|
Registration:
|
|
Free Registration
|
|
E-mail:
|
|
tristan@xtalks.com
|
|
|
|
|
|
|
|
|
|
|
|